Novartis: Meningitis trials

The registry lists 28 Meningitis studies with Novartis as lead sponsor. 0 are open to participants now and 28 have results posted.

Phase 2 6Phase 3 20Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.CompletedNCT02141516Phase 3Results posted
• Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese ChildrenCompletedNCT02139228Phase 3Results posted
• Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.CompletedNCT01973218Phase 3Results posted
• Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster DoseCompletedNCT01823536Phase 4Results posted
• Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in RussiaCompletedNCT01725217Phase 3Results posted
• A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk AdultsCompletedNCT01478347Phase 3Results posted
• Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy ToddlersCompletedNCT01434680Phase 2Results posted
• A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in AdolescentsCompletedNCT01424644Phase 4Results posted
• Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study VaccinesCompletedNCT01367158Phase 2Results posted
• Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate VaccineCompletedNCT01345721Phase 3Results posted
• A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in KoreaCompletedNCT01274897Phase 3Results posted
• Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of LifeCompletedNCT01214837Phase 3Results posted
• Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate VaccineCompletedNCT01148017Phase 3Results posted
• A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWYCompletedNCT01018732Phase 2Results posted
• Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old InfantsCompletedNCT00937521Phase 2Results posted
• Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate VaccineCompletedNCT00856297Phase 3Results posted
• Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsCompletedNCT00806195Phase 3Results posted
• Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and ToddlersCompletedNCT00667602Phase 3Results posted
• Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy ToddlersCompletedNCT00626327Phase 3Results posted
• Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy ChildrenCompletedNCT00616421Phase 3Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In AdolescentsCompletedNCT00518180Phase 3Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In InfantsCompletedNCT00474526Phase 3Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy AdultsCompletedNCT00474487Phase 3Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and AdultsCompletedNCT00450437Phase 3Results posted
• Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 YearsCompletedNCT00329901Phase 3Results posted
• Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of AgeCompletedNCT00329849Phase 3Results posted
• Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)CompletedNCT00310856Phase 2Results posted
• Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.CompletedNCT00310817Phase 2Results posted